60 results
S-8
EX-10.1
COCP
Cocrystal Pharma Inc
11 May 18
Registration of securities for employees
4:16pm
Award” shall mean an Award subject to the achievement of certain performance goal or goals as described in Section 12 below.
1.26. “Performance Share … basis, including modifications of performance goals and changes in the length of performance periods; provided, however, that with respect to Performance
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
to support an IND application,” Dr. Lee added.
“Among our goals this year is to complete the CC-42344 Phase 1 influenza study and to initiate two … structure-based drug discovery platform technology,” said James Martin, CFO and co-interim CEO. “We are well positioned to execute on these goals
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
goals given our clean capital structure, cost-efficient business model and a cash balance we believe is sufficient to fund planned operations into 2024 … , including statements regarding our goals of initiating two Phase 1 studies for our COVID-19 programs in 2022, our expectations of reporting data from
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
development programs and have strengthened our financial position to achieve our goals.”
Cocrystal employs unique structure-based technologies and Nobel Prize
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
11 Mar 19
Cocrystal Pharma Announces Closing of Private Placement
8:35am
for progress in 2019 and achievement of goals, driving significant shareholder value and closing the private placement. The words “believe,” “may
8-K
EX-99.1
p25xxdb cz
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-10.2
oeuw3w2c3fz
8 Jan 14
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-10.1
5i89l60se
8 Jan 14
Completion of Acquisition or Disposition of Assets
12:00am
424B5
cd4jg yalo
26 Aug 20
Prospectus supplement for primary offering
5:30pm
424B5
sgcreqq9 boc
27 Aug 20
Prospectus supplement for primary offering
5:24pm
424B5
bf2zh9ho
1 Jul 20
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
k5yx ps7jcf
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
8-K
EX-99.1
wdh4 fkwqt06
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-99.1
0a0i2ss3yk5v9wh06d
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
b7g qtdup9
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
424B5
ubig 5p3r35
31 Oct 19
Prospectus supplement for primary offering
4:02pm
424B5
aea9 vvpd
31 Jan 20
Prospectus supplement for primary offering
8:03am
424B5
54pd1iv
31 Jan 20
Prospectus supplement for primary offering
8:01am